Ukutyunjwa kweziyobisi eziNtsha zeNkedama kuNyango lweFollicular Lymphoma

Ibhalwe ngu umhleli

I-CASI Pharmaceuticals, Inc., inkampani yase-US ye-biopharmaceutical egxile ekuphuhliseni nasekuthengiseni amayeza onyango kunye neemveliso zamachiza, ibhengezwe namhlanje, ukuba i-US Food and Drug Administration (i-FDA) inike i-Orphan Drug Designation (ODD) kwiqabane layo i-BioInvent International AB, ngenxa yokuba I-BI-1206, i-anti-FcyRllB yophando, unyango lwe-follicular lymphoma (FL), eyona ndlela ixhaphakileyo ye-Non-Hodgkin lymphoma (NHL) ekhula ngokucothayo.

Print Friendly, PDF & Email

I-BI-1206 ngumgqatswa weyeza eliphambili le-BioInvent kwaye kungoku nje iphandwa kulingo lweSigaba 1/2 ezibini. Omnye uvavanya i-BI-1206 indibaniselwano kunye ne-rituximab yonyango lwe-Non-Hodgkin lymphoma, ebandakanya izigulane ezine-FL, i-MCL kunye ne-marginal zone lymphoma (MZL) eziye zabuyela emva okanye ezichasayo kwi-rituximab. Ulingo lwesibini lweSigaba se-1/2 luphanda i-BI-1206 ngokudibanisa ne-anti-PD1 yonyango i-Keytruda® (pembrolizumab) kwiithumba eziqinileyo.

UGqr. Wei-Wu He, uSihlalo weCASI, kunye ne-CEO uthe, “I-BioInvent isaqhubeka nokwenza inkqubela ngophuhliso kunye nesikhokelo solawulo se-BI-1206. Ukwamkelwa kwe-CTA e-China ngoDisemba ka-2021 kunye ne-FDA ye-Orphan Orphan Drug Designation yamva nje ibonisa amandla anamandla ale antibody yodidi lokuqala. I-CASI inamalungelo orhwebo aseTshayina e-BI-1026, kwaye iqela lethu lilungiselela isifundo seklinikhi saseTshayina. I-CASI kunye ne-BioInvent ngamaqabane angenamthungo kwaye banenjongo efanayo yokunceda izigulana ezinobuchwepheshe obutsha bomayeza.

Print Friendly, PDF & Email

Iindaba ezidibeneyo

Malunga nombhali

umhleli

Umhleli oyintloko we-eTurboNew nguLinda Hohnholz. Uzinze kwi-eTN HQ e-Honolulu, eHawaii.

Shiya Comment